Male hormone-interfering drugs and meningioma development.

Abstract

BACKGROUND:

Extremely strong associations between male hormone-interfering drugs and meningiomas have been reported in two previous studies, but these findings are limited by small size of the study populations and possibly by surveillance- and selection bias. Thus, such possible and indeed very interesting association must be investigated in a large, unselected cohort. Accordingly, the aim of this study was to determine whether patients exposed to male hormone-interfering drugs had a higher risk of meningioma development in a nationwide cohort study.

METHODS:

A retrospective Danish nationwide cohort study with follow-up from January 1, 1996 to December 31, 2016. Exposure was use of male hormone-interfering drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen). Hazard ratio of first-time diagnosis of meningioma according to drug use was estimated using Cox proportional hazards model with adjustment for age and birth year.

RESULTS:

The cohort included 244,696 men of which 64,047 had used male hormone-interfering drugs. Overall 444 meningiomas occurred during follow-up. No significant association was observed between use of male hormone-interfering drugs and the occurrence of meningioma (hazard ratio 1.02, 95% confidence interval 0.82-1.27). Similar results were observed 0-1, 2-4, and 5+ years after first use. In explorative analyses, no elevated risk association was observed for specific drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen).

CONCLUSION:

As opposed to previous studies, we found no evidence of an increased risk of meningioma in men treated with male hormone-interfering drugs.

• Authors: Laura Giraldi, Jørgen Vinsløv Hansen, Jan Wohlfahrt, Mads Melbye, Kåre Fugleholm, Tina Nørgaard Munch
• Journal: Neuro-oncology advances (Neurooncol Adv) 2019 May-Dec Vol. 1 Issue 1 Pg. vdz046 ISSN: 2632-2498 [Electronic] England
• PMID: 32642670 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.